Data Quality Notice
Data quality observations on this stock — see hidden fields below.
Reported as ticker: SUVEN· We're continuously improving data quality. Contact support if this persists.
SUVEN LIFE SCIENCES LTD
SUVEN · Pharma · NSE
₹202
Current Market Price
Fair Value (DCF)
₹619
Margin of Safety
+206.5%
Updated just now
YieldIQ Score
34/100
Piotroski F-Score
2/9
Economic Moat
None
Confidence
300512035%
ROE
—
Debt/Equity
0.00
WACC
9.7%
Market Cap
₹5,328 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
—
Return on capital employed
EV / EBITDA
—
Enterprise multiple
Debt / EBITDA
—
Leverage vs earnings
Interest Coverage
—
EBIT covers interest
Current Ratio
—
Short-term liquidity
Asset Turnover
0.05×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-17.5%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹202.05
Bear case
₹0
MoS -Infinity%
Base case
₹619.2
MoS +67.4%
Bull case
₹665.64
MoS +69.6%
Ratio Trends
SUVEN · last 8 annual periods
ROE
-9.8%
ROCE
-140.8%
Operating Margin
—
Debt / Equity
—
PE
—
EV / EBITDA
—
Historical Financials
SUVEN · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹13.5 Cr | ₹11.8 Cr | ₹261.1K Cr | ₹238.5K Cr | ₹6.7 Cr | -16.2% |
| EBITDA | — | ₹-117 Cr | ₹-111 Cr | ₹-99.4 Cr | ₹-155 Cr | — |
| EBIT | ₹-76.7 Cr | ₹-121 Cr | ₹-2759.1K Cr | ₹-2751.3K Cr | — | — |
| PAT | ₹-72.2 Cr | ₹-122 Cr | ₹-2764.5K Cr | ₹-2654.1K Cr | ₹-161 Cr | — |
| EPS (diluted) | ₹-5.67 | ₹-9.57 | ₹-1.17 | ₹-1.22 | — | — |
| CFO | ₹-133 Cr | ₹-128 Cr | ₹-20793.0K Cr | ₹-8261.9K Cr | ₹-154 Cr | — |
| CapEx | — | — | — | — | ₹-37.3 Cr | — |
| FCF | — | — | — | — | ₹-191 Cr | — |
| Total Assets | — | ₹108 Cr | ₹38891.1K Cr | ₹28490.3K Cr | ₹135 Cr | +5.8% |
| Total Debt | — | — | ₹0.0 Cr | ₹0.0 Cr | ₹0.0 Cr | — |
| Shareholders' Equity | — | — | ₹37531.9K Cr | ₹27004.1K Cr | ₹110 Cr | -95.9% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SUVEN vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| FDC FDC | — | — | Pending | 11.7% | — |
| AARTIPHARM AARTIPHARM | — | — | Pending | 13.7% | — |
| SUDEEPPHRM SUDEEPPHRM | — | — | Pending | 28.1% | — |
| SHILPAMED SHILPAMED | — | — | Pending | 3.3% | — |
| PGHL PROCTER & GAMBLE HEALTH L | -32.5% | 45 | Above Fair Value | 3.1% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for SUVEN in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. SUVEN LIFE SCIENCES LTD (SUVEN.NS) trades at 202.05 vs a model fair value of 619.20, a gap of 206.5%. Piotroski F-score: 2/9. Moat label:...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of SUVEN →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SUVEN →
Compare
Head-to-head with peers
Compare SUVEN side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SUVENNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.